Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial, Bacainn’s First Clinical Candidate for the Treatment of Ulcerative Colitis BT051 IND Clearance Phase 1 Clinical Trial Initiation CONCORD, Mass. — Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDA’s [...]
Aliquam sit amet ipsum eu tellus tincidunt commodo. Aenean metus tellus, vehicula at nisl vel, laoreet gravida risus. Integer nec fringilla neque. Vivamus tincidunt dui vitae augue.
Suspendisse maximus, quam eget gravida consectetur, mauris urna porta velit, egestas facilisis augue arcu vitae magna. Curabitur rutrum augue augue, non sodales eros porttitor.
Integer molestie eros at urna sodales pharetra quis vitae diam. Sed quis dui ultrices, suscipit eros quis, faucibus eros. Vivamus lectus nisl, malesuada nec viverra eu, facilisis ut odio.
